| SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal | Sarah de Crescenzo | 02/20/20 | Seattle |
| Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug | Frank Vinluan | 02/20/20 | San Francisco |
| Teva Drug Fails to Beat Placebo in Pediatric Tourette Patient Trials | Sarah de Crescenzo | 02/19/20 | National |
| Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test | Sarah de Crescenzo | 02/18/20 | San Francisco |
| Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic | Frank Vinluan | 02/18/20 | Boston |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks | Frank Vinluan | 02/13/20 | National |
| Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer | Frank Vinluan | 02/12/20 | San Francisco |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s | Frank Vinluan | 02/10/20 | National |
| Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More | Sarah de Crescenzo | 02/07/20 | National |
| Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer | Frank Vinluan | 02/06/20 | San Francisco |
| Coda Bio Acquires Drug Candidates to Pair With Engineered Receptors | Sarah de Crescenzo | 02/06/20 | San Francisco |
| Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate | Sarah de Crescenzo | 02/05/20 | San Francisco |
| Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff | Frank Vinluan | 02/05/20 | New York |
| Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA | Frank Vinluan | 02/04/20 | National |
| Verily, Santen See Ophthalmology Opportunity Via New Joint Venture | Sarah de Crescenzo | 02/04/20 | San Francisco |
| $750M Fund Looks to Software Sector to Drive Future of Biotech | Sarah de Crescenzo | 02/04/20 | National |
| Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic | Sarah de Crescenzo | 02/03/20 | New York |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs | Sarah de Crescenzo | 01/31/20 | San Diego |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| BIO Report: More Work Needed to Improve Diversity at Biotech Firms | Sarah de Crescenzo | 01/30/20 | National |
| With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14 | Frank Vinluan | 01/30/20 | San Francisco |
| Black Diamond’s Upsized IPO Raises $201M to Advance Its Cancer Drug R&D | Frank Vinluan | 01/30/20 | Boston |
| Histogen, Timber Pharma Plan Reverse Mergers to Join Public Markets | Sarah de Crescenzo | 01/28/20 | San Diego |
| BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely | Sarah de Crescenzo | 01/28/20 | Boulder/Denver |
| Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report | Gareth Macdonald | 01/28/20 | National |
| Life Sciences IPOs Target Collective Raise of More Than $600M This Week | Sarah de Crescenzo | 01/27/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
